Table 2. Comparison of 87 NSCLC patient characteristics between the OR (CR + PR) group and the non-OR (SD + PD) group.
| Factor | OR (N=44) | Non-OR (N=43) | P |
|---|---|---|---|
| Age (years) | |||
| >65 | 20 | 23 | 0.454 |
| ≤65 | 24 | 20 | |
| Gender | |||
| Female | 6 | 8 | 0.528 |
| Male | 38 | 35 | |
| Complication | |||
| Yes | 20 | 21 | 0.752 |
| No | 24 | 22 | |
| Smoking history (packs-year) | |||
| >30 | 28 | 24 | 0.457 |
| ≤30 | 16 | 19 | |
| Tumor location | |||
| Peripheral | 30 | 31 | 0.690 |
| Central | 14 | 12 | |
| Pathology | |||
| Squamous | 22 | 19 | 0.587 |
| Non-squamous | 22 | 24 | |
| T stage | |||
| 1 | 18 | 15 | 0.314 |
| 2 | 16 | 18 | |
| 3 | 2 | 6 | |
| 4 | 8 | 4 | |
| N stage | |||
| 0 | 21 | 17 | 0.597 |
| 1 | 3 | 1 | |
| 2 | 11 | 13 | |
| 3 | 9 | 12 | |
| Chemotherapy | |||
| Yes | 23 | 22 | 0.918 |
| No | 21 | 21 | |
| RT technology | |||
| SBRT | 15 | 12 | 0.533 |
| IMRT | 29 | 31 | |
| Concurrent CRT | |||
| Yes | 15 | 9 | 0.128 |
| No | 29 | 34 |
NSCLC, non-small cell lung cancer; OR, objective response; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; SBRT, stereotactic body radiation therapy; IMRT, intensity modulated radiotherapy; CRT, chemoradiotherapy.